



Mersana Therapeutics to Present at Cowen and Company 36th Annual Health Care Conference

March 3, 2016

CAMBRIDGE, Mass., March 3, 2016 -- Mersana Therapeutics, Inc. today announced that Donald Bergstrom, M.D., Ph.D., Chief Medical Officer, will present at the Cowen and Company 36th Annual Health Care Conference at the Boston Marriott Copley Place on Wednesday, March 9, 2016, at 8:30 a.m. ET.

About Mersana Therapeutics

Mersana Therapeutics is advancing a proprietary pipeline of targeted oncology therapeutics leveraging its game-changing Fleximer® immunoconjugate technology. Mersana's first product candidate XMT-1522 has the potential to address significant unmet needs and improve patient outcomes in multiple oncology indications. Fleximer-based immunoconjugate molecules have been shown to have superior efficacy, including with targets previously considered not amenable to antibody-drug conjugate approaches. Mersana has collaborations utilizing Fleximer technology with Takeda, Merck KGaA, and Asana BioSciences. For more information, please visit www.mersana.com.

###

Media Contact

6 Degrees
Tony Plohoros
tplohoros@6degreespr.com
(908) 591-2839

Investors Contact

Stern Investor Relations, Inc.
Jesse Baumgartner
Jesse@sternir.com
(212) 362-1200